Press release16.07.2026 klo 11.40Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting
Press release25.06.2026 klo 16.00Novakand Pharma consolidates forces for the development of orphan drugs against cancer
Press release31.03.2026 klo 09.00Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors
Press release02.03.2026 klo 08.00Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
Press release25.02.2026 klo 17.45The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines
Press release12.02.2026 klo 18.45Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines
Press release06.02.2026 klo 09.00Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover
Regulatory press release22.12.2025 klo 09.00Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover
Regulatory press release21.11.2025 klo 09.00Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
Press release09.10.2025 klo 10.00Novakand Pharma provides an update on the ongoing reverse take over process
Regulatory press release23.09.2025 klo 16.00Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board
Regulatory press release18.09.2025 klo 19.00Kancera initiates process to seek stakeholders for a reverse take over
Regulatory press release28.08.2025 klo 09.00Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851
Press release16.06.2025 klo 09.30Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145
Regulatory press release13.06.2025 klo 09.00Kancera reports positive top-line results from the KANDOVA study
Regulatory press release05.06.2025 klo 09.00Kancera reports positive outcome of pre-IND meeting with FDA
Regulatory press release23.05.2025 klo 09.00Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851